{"entity":{"id":"nct06521866","kind":"trial","name":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of serplulimab in colorectal cancer, run by Fudan University, now recruiting.","summary":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06521866 by Fudan University, with a registry enrolment figure of 208 participants, started 2025-03-01 and due to reach its primary completion in 2026-08-01. Interventions recorded: Serplulimab; Chemotherapy; SABR; Targeted therapy. Conditions listed: Advanced Colorectal Carcinoma; Immunotherapy. Primary outcome: PFS. Colorectal eligibility wording from the registry: \"Histologically confirmed metastatic colorectal cancer (Stage IV, UICC), with initially unresectable metastases or refusal of surgery;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06521866","url":"https://clinicaltrials.gov/study/NCT06521866"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["serplulimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06521866","phase":"2","setting":"A Prospective, Randomized, Phase II, Multicenter Clinical Study of Serplulimab Combined with First-Line Targeted Therapy and Chemotherapy with or Without Radiation in the First-Line Treatment of Advanced Colorectal Cancer","sponsor":"Fudan University","participation":[{"nct":"NCT06521866","source":"https://clinicaltrials.gov/study/NCT06521866","fetchedAt":"2026-10-07T16:54:45.035Z","studySha256":"b204675e216b2113054cf75b9222fc9a4584e1d078a622de66398faf13409589","overallStatus":"RECRUITING","lastUpdatePosted":"2025-03-14","leadSponsor":"Fudan University","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":208,"enrolmentType":"ESTIMATED","siteCount":10,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-03-01","startedType":"actual","enrolled":208,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06521866/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}